What is Nipitant?

Nipitant (codenamed LY2216684) is a selective 5-HT1A partial agonist under development by Eli Lilly and Company for the treatment of schizophrenia.[1][2] It entered phase 3 clinical trials in December 2015[3] but development was discontinued in July 2019 after an interim analysis suggested it would fail to provide a sufficiently large benefit.[4] The FDA had previously granted nipitant fast track designation and orphan drug status.[5]